Cutting Edge: Expression of Chemokine Receptor CXCR1 on Human Effector CD8+ T Cells

Hiroshi Takata, Hiroko Tomiyama, Mamoru Fujiwara, Naoki Kobayashi and Masafumi Takiguchi

`J Immunol` 2004; 173:2231-2235; doi: 10.4049/jimmunol.173.4.2231
http://www.jimmunol.org/content/173/4/2231

References
This article cites 19 articles, 9 of which you can access for free at:
http://www.jimmunol.org/content/173/4/2231.full#ref-list-1

Subscription
Information about subscribing to `The Journal of Immunology` is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Cutting Edge: Expression of Chemokine Receptor CXCR1 on Human Effector CD8\(^+\) T Cells\(^1\)

Hiroshi Takata, Hiroko Tomiyama, Mamoru Fujiwara, Naoki Kobayashi, and Masafumi Takiguchi\(^2\)

IL-8 is a potent inflammatory cytokine that induces chemotaxis of neutrophils expressing CXCR1 and CXCR2, thus indicating its involvement in the migration of these cells to inflammatory sites where bacteria proliferate. Presently, we showed that CXCR1\(^+\) cells were predominantly found among CD8\(^+\) T cells having effector phenotype, and that the expression of CXCR1 was positively correlated with that of perforin, suggesting that CXCR1 is expressed on effector CD8\(^+\) T cells. Indeed, human CMV-specific CD8\(^+\) T cells from healthy individuals, which mostly express the effector phenotype and have cytolytic function, expressed CXCR1, whereas EBV-specific CD8\(^+\) T cells, which mostly express the memory phenotype and have no cytolytic function, did not express this receptor. The results of a chemotaxis assay showed that the migration of CXCR1\(^+\)CD8\(^+\) T cells was induced by IL-8. These results suggest that the IL-8-CXCR1 pathway plays an important role in the homing of effector CD8\(^+\) T cells. The Journal of Immunology, 2004, 173: 2231–2235.

Memory and effector CD8\(^+\) T cells play an important role in the eradication of viruses and tumor cells through their ability to produce various factors involved in the suppression of viral replication (1, 2) and to cause cytolysis of virus-infected and tumor cells (3). Effector CD8\(^+\) T cells have the ability to kill target cells through the action of perforin and Fas ligands. These cells express a high level of perforin and produce cytokines such as TNF-\(\alpha\) and IFN-\(\gamma\) (4). Previous studies suggested that particular expression patterns of costimulatory receptors CD27 and CD28 as well as CD45RA or CD45RO are associated with the naive, memory, and effector functions of human CD8\(^+\) T cells (5–8). Multicolor flow cytometric analysis demonstrated that effector and memory/effector CD8\(^+\) T cells, both of which have cytolytic activity, have the phenotypes of CD27\(^-\)CD28\(^-\)CD45RA\(^+\)/\(^-\) and CD27\(^+\)/CD28\(^+\)CD45RA\(^+\)/\(^-\), respectively (4).

The chemokine receptor CCR7 is useful for discriminating naive and central memory CD8\(^+\) T cells from memory/effector and effector CD8\(^+\) T cells (9). CCR7 functions as a homing receptor and is expressed on naive CD8\(^+\) T cells and on a subset of memory CD8\(^+\) T cells. A previous study resulted in the following classification of CD8\(^+\) T cells based on CCR7 and CD45RA: naive, CCR7\(^+\)CD45RA\(^+\); central memory, CCR7\(^+\)CD45RA\(^-\); and effector/memory, CCR7\(^-\)CD45RA\(^+\)/\(^-\) (9). A recent study showed that the CCR5 chemokine receptor is expressed on memory, memory/effector, and effector CD8\(^+\) T cells, with the number of CCR5\(^+\)CD8\(^+\) T cells decreasing during the differentiation of CD27\(^+\)/CD28\(^+\)CD45RA\(^+\) memory T cells into CD27\(^-\)CD28\(^-\)CD45RA\(^+\)/\(^-\) effector T cells (5). These findings imply that these two chemokine receptors are also useful for the classification of CD8\(^+\) T cells.

Two IL-8 receptors, CXCR1 and CXCR2, are expressed on the surface of neutrophils, monocytes, mast cells, NK cells, and eosinophils (10–12). IL-8 can attract these cells (11), indicating that these IL-8 receptors play an important role in the migration of these cells to sites of inflammation. Thus, the cells expressing these IL-8 receptors are involved in innate immunity. Concerning the cells involved in acquired immunity, such as CD8\(^+\) and CD4\(^+\) T cells, a previous study showed that some CD8\(^+\) T cells express these receptors (13). However, there has been no detailed analysis regarding the expression of these receptors on CD8\(^+\) T cells.

In the present study, we investigated the expression and function of CXCR1 on human CD8\(^+\) T cells. The results showed that CXCR1 was expressed on effector CD8\(^+\) T cells and that the migration of CXCR1\(^+\)CD8\(^+\) T cells was induced by IL-8. Our present data have thus revealed an important role played by CXCR1 in acquired immunity.

Materials and Methods

Antibodies

Anti-CD27-FITC, anti-CXCR1-FITC (5A12), anti-CD28-allophycocyanin, and anti-perforin-FITC mAbs were obtained from BD Pharmingen (San Diego, CA). Anti-CD45RA-EC2 was purchased from Immunotech (Marseille, France). Anti-CD3-FITC, anti-CD8-allophycocyanin, anti-CXCR1-PE (427/05.111), and anti-CXCR2-PE (483/11.211) mAbs were obtained from DakoCytomation (Glostrup, Denmark). Human IgG came from Sigma-Aldrich (St. Louis, MO).

Division of Viral Immunology, Center for AIDS Research, Kumamoto University, Honjo, Kumamoto, Japan

Received for publication March 23, 2004. Accepted for publication June 22, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

\(^1\) This work was supported by a grant-in-aid for scientific research from the Ministry of Health, Labor and Welfare, the government of Japan.

\(^2\) Address correspondence and reprint requests to Dr. Masafumi Takiguchi, Division of Viral Immunology, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan. E-mail address: masafumi@kaiju.medic.kumamoto-u.ac.jp
HLA-class I tetramers

HLA-class I-peptide tetrameric complexes (tetramers) were synthesized as previously described (14). The human CMV (HCVM)\(^*\) CTL epitope (HCVM-1 pp65\(_{499-508}\) NLVPWMATV; Ref. 15) and the EBV CTL epitope (EBV 3B 503, NLVPMVATV; Ref. 15) and the EBV CTL epitope (EBV 3B 503, NLVPMVATV; Ref. 16) were used for refolding of HLA-A*0201 or HLA-A*0206 molecules and HLA-A*1101 molecules, respectively. PE-labeled streptavidin (Molecular Probes, Eugene, OR) or allophycocyanin-Cy7-labeled streptavidin (Cedarlane Laboratories, Hornby, Ontario, Canada) was used for generation of tetramers.

Flow cytometric analysis

PBMCs from healthy individuals were stained with anti-CD3 mAb, anti-CD8 mAb, and anti-CXCR1 mAb or anti-CXCR2 mAb. The cells were incubated at 4°C for 30 min, and were then washed twice with PBS containing 10% newborn calf serum (PBS/10% NCS). The percentage of CXCR1\(^+\) CD8\(^+\) T cells in the total CD8\(^+\) T cells was determined by using a FACSCalibur (BD Biosciences, San Jose, CA). Furthermore, to clarify CXCR1 expression in each CD27\(/\)CD45RA subset of total CD8\(^+\) T cells, we purified CD8\(^+\) T cells from PBMC by using anti-CD8-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The percentage of CD8\(^+\) T cells among the purified cells was $>$98%. Purified CD8\(^+\) T cells were stained with anti-CD27 mAb, anti-CD28 mAb, anti-CD45RA mAb, and anti-CXCR1 mAb. The cells were incubated at 4°C for 30 min, and were then washed twice with PBS/10% NCS. The percentage of CXCR1\(^+\) cells in each subset was measured by using the FACSCalibur.

To define intracellular perforin expression in CXCR1\(^+\) and CXCR1\(^-\) subsets of total CD8\(^+\) T cells, we stained PBMCs with anti-CD8 mAb and anti-CXCR1 mAb, fixed them in 4% paraformaldehyde at 4°C for 20 min, and then permeabilized them at 4°C for 10 min with PBS containing 0.1% saponin and 20% NCS (permeabilizing buffer). The cells were washed with permeabilizing buffer and then resuspended in 50 μl of the same buffer. After anti-perforin mAb had been added, the cell suspension was incubated at 4°C for 30 min, and the cells were then washed three times in the permeabilizing buffer at 4°C. PE-labeled mouse IgG1 was used as a negative control.

To determine the expression of CXCR1 on HCMV-specific and EBV-specific CD8\(^+\) T cells, we purified PBMCs with anti-CD8 mAb and anti-CXCR1 mAb, fixed them in 4% paraformaldehyde at 4°C for 20 min, and then permeabilized them at 4°C for 10 min with PBS containing 0.1% saponin and 20% NCS (permeabilizing buffer). The cells were washed with permeabilizing buffer and then resuspended in 50 μl of the same buffer. After anti-perforin mAb had been added, the cell suspension was incubated at 4°C for 30 min, and the cells were then washed three times in the permeabilizing buffer at 4°C. PE-labeled mouse IgG1 was used as a negative control.

Results and Discussion

A previous study showed that IL-8 receptors CXCR1 and CXCR2 were expressed on the surface of some CD8\(^+\) T cells (13). To confirm this, we investigated the surface expression of CXCR1 and CXCR2 on total CD8\(^+\) T cells. We first examined their surface expression on PBMC by using anti-CXCR1 and anti-CXCR2 mAbs. CXCR1\(^+\) cells were detected among both small-size (lymphocytes) and large-size (monocytes) cells, whereas CXCR2\(^+\) cells were found only among the latter (Fig. 1A). These results support a previous finding that both IL-8 receptors are expressed on monocytes (10), and suggest that only CXCR1 is expressed on T cells. To clarify the expression of these receptors on T cells, we examined the CXCR1 and CXCR2 expression on T cells among PBMCs from healthy individuals by using anti-CD3, anti-CD8, and anti-CXCR1 or anti-CXCR2 mAbs. A representative result is shown in Fig. 1B. A significant number of CD8\(^+\) T cells expressed CXCR1, whereas almost no CD8\(^+\) T cells expressed CXCR2 (Fig. 1B). In contrast, CD8\(^-\) T cells did not express CXCR1 (data not shown). The lack of CXCR2 expression on CD8\(^+\) T cells was confirmed by examining the cells from nine healthy individuals. The expression of CXCR1 varied among these nine individuals, with the percentage of CXCR1\(^+\) CD8\(^+\) T cells among the total CD8\(^+\) T cells ranging from 7.6 to 51.0% (mean $\pm$ SD, 22.6 $\pm$ 15.6%; Fig. 1C). These results indicate that a given subset of CD8\(^+\) T cells expresses CXCR1, but are in conflict with a previous finding that CD8\(^-\) T cells express CXCR2 (10).

Our recent study showed that naive, memory, and effector CD8\(^+\) T cell subsets can be classified by CD27, CD28, and CD45RA (4). Therefore, we investigated the surface expression of CXCR1 on each CD27\(/\)CD45RA subset in the total CD8\(^+\) T cells. Total CD8\(^+\) T cells were isolated from PBMC of 10 healthy individuals, and then analyzed by four-color flow cytometric analysis with anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR1 mAb. CXCR1-positive cells were found in subsets with CD27\(^-\)CD28\(^+\)CD45RA\(^+\) and (13). To confirm this, we investigated the surface expression of CXCR1 and CXCR2 on total CD8\(^+\) T cells. We first examined their surface expression on PBMC by using anti-CXCR1 and anti-CXCR2 mAbs. CXCR1\(^+\) cells were detected among both small-size (lymphocytes) and large-size (monocytes) cells, whereas CXCR2\(^+\) cells were found only among the latter (Fig. 1A). These results support a previous finding that both IL-8 receptors are expressed on monocytes (10), and suggest that only CXCR1 is expressed on T cells. To clarify the expression of these receptors on T cells, we examined the CXCR1 and CXCR2 expression on T cells among PBMCs from healthy individuals by using anti-CD3, anti-CD8, and anti-CXCR1 or anti-CXCR2 mAbs. A representative result is shown in Fig. 1B. A significant number of CD8\(^+\) T cells expressed CXCR1, whereas almost no CD8\(^+\) T cells expressed CXCR2 (Fig. 1B). In contrast, CD8\(^-\) T cells did not express CXCR1 (data not shown). The lack of CXCR2 expression on CD8\(^+\) T cells was confirmed by examining the cells from nine healthy individuals. The expression of CXCR1 varied among these nine individuals, with the percentage of CXCR1\(^+\) CD8\(^+\) T cells among the total CD8\(^+\) T cells ranging from 7.6 to 51.0% (mean $\pm$ SD, 22.6 $\pm$ 15.6%; Fig. 1C). These results indicate that a given subset of CD8\(^+\) T cells expresses CXCR1, but are in conflict with a previous finding that CD8\(^-\) T cells express CXCR2 (10).

Our recent study showed that naive, memory, and effector CD8\(^+\) T cell subsets can be classified by CD27, CD28, and CD45RA (4). Therefore, we investigated the surface expression of CXCR1 on each CD27\(/\)CD45RA subset in the total CD8\(^+\) T cells. Total CD8\(^+\) T cells were isolated from PBMC of 10 healthy individuals, and then analyzed by four-color flow cytometric analysis with anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR1 mAb. CXCR1-positive cells were found in subsets with CD27\(^-\)CD28\(^+\)CD45RA\(^+\) and

Abbreviations used in this paper: HCMV, human CMV; GCP, granulocyte chemotactic protein; MFI, mean fluorescence intensity; NCS, newborn cow serum.

![FIGURE 1. Surface expression of CXCR1 on CD8\(^+\) T cells. A. Surface expression of CXCR1 and CXCR2 on PBMC. PBMCs from a given individual (U16) were stained with anti-CXCR1 or -CXCR2 mAb. Frequency of CXCR1\(^+\) and of CXCR2\(^+\) cells in both small- and large-size cell populations was analyzed by flow cytometry. The percentage of CXCR1\(^+\) or CXCR2\(^+\) cells is given in each plot. B. Surface expression of CXCR1 and CXCR2 on CD8\(^+\) T cells. PBMC from individual U16 were stained with anti-CD3, anti-CD8, and anti-CXCR1 or anti-CXCR2 mAbs. The CD3\(^+\) CD8\(^-\) subset was gated, and then the surface expression of CXCR1 and of CXCR2 was analyzed. The percentage of CXCR1\(^+\) cells or CXCR2\(^+\) cells is given in each plot. C. Variation of CXCR1 and CXCR2 expression on CD8\(^+\) T cells in nine healthy individuals. The mean percentage and SD of CXCR1\(^+\) cells and CXCR2\(^+\) cells in the CD3\(^+\)CD8\(^-\) subset are presented in the figures.](http://www.jimmunol.org/)

Downloaded from http://www.jimmunol.org/ by guest on April 10, 2017
CD27lowCD28−CD45RA+− phenotypes (Fig. 2A). Approximately 60% of the CD27−CD28CD45RA+− cells expressed CXCR1, whereas only 20% of CD27lowCD28−CD45RA+− cells expressed this receptor (Fig. 2B). Because these subsets have cytotoxic activity (4, 6), these results suggest that CXCR1 is expressed only on the subsets with cytolytic effector function.

Because CD27−CD28−CD45RA+− subsets express a much higher level of perforin than other CD27CD28CD45RA subsets (4), we suspected that CXCR1 expression would be positively correlated with perforin expression in CD8+ T cells. Therefore, we analyzed the correlation between CXCR1 and perforin expression on/in CD8+ T cells from five healthy individuals. Almost all CXCR1+ cells were perforin-positive cells, although perforin-positive cells included both CXCR1+ and CXCR1− cells (Fig. 3A). To analyze semiquantitatively the co-expression of CXCR1 and perforin in CD8+ T cells, we divided the perforin-positive population into 4–8 fractions according to the level of perforin expression. The frequency of CXCR1+ cells (Fig. 3B) and expression level of CXCR1 (data not shown) were positively related to perforin expression, demonstrating that CXCR1 expression is strongly associated with perforin expression in CD8+ T cells. These findings support the idea that CXCR1 is a marker for cytolytic effector CD8+ T cells.

Because CCR5 is expressed on memory and effector CD8+ T cells (4, 6), it may be assumed that CXCR1+/CCR5+ cells would exist among CD8+ T cells. In fact, CXCR1+/CCR5+ cells were found mostly in CD27−CD28−CD45RA+− subsets (data not shown). These CXCR1+/CCR5+ cells expressed lower levels of CXCR1 and CCR5 than the CXCR1−CCR5− cells or CXCR1−CCR5+ cells, suggesting that CXCR1+/CCR5+ cells are an intermediate type between the CXCR1+CCR5− cells and CXCR1−CCR5+ cells in these effector subsets.

HCMV-specific CD8+ T cells have the CD27−CD28−CD45RA+− effector phenotype or CD27lowCD28−CD45RA+− memory/effector phenotype and the ability to kill target cells (4), whereas EBV-specific CD8+ T cells have the CD27−CD28−CD45RA− memory phenotype and fail to kill target cells (6), implying that HCMV-specific CD8+ T cells would express CXCR1 and EBV-specific ones would not. Therefore, we investigated the expression of CXCR1 on HCMV-specific and EBV-specific CD8+ T cells.

HCMV and the HLA-A*1101/EBV tetramers, respectively, together with anti-CD8 and anti-CXCR1 mAb. HCMV-specific CD8+ T cells expressed CXCR1, whereas very few EBV-specific CD8+ T cells expressed this receptor (Fig. 4A). Because HCMV-specific and EBV-specific CD8+ T cells expressed effector and memory phenotypes, respectively (Fig. 4A), the results indicate that viral epitope-specific CD8+ T cells

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Surface expression of CXCR1 on CD8+ T cells with effector and memory/effector phenotypes. A, Frequency of CXCR1+ cells in each CD27CD28CD45RA subset of CD8+ T cells. CD8+ T cells were isolated from a given individual (U25) and then stained with anti-CD27, anti-CD28, anti-CD45RA, and anti-CXCR1 mAbs. Each CD27CD28CD45RA subset was gated and then analyzed for CXCR1 expression. The percentage of CXCR1+ cells in each subset is shown in each plot. B, Frequency of CXCR1+ cells in each CD27CD28CD45RA subset of CD8+ T cells from 10 individuals. The mean percentage and SD of CXCR1+ cells in each subset are indicated.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Coexpression of CXCR1 and perforin in CD8+ T cells. PBMC from five individuals were stained with anti-CD8, anti-perforin, and anti-CXCR1 or mouse IgG1 mAb. The CD8+ subset was gated and then analyzed for CXCR1 and perforin expression. N, Mean fluorescence intensity (MFI) between perforin-positive and perforin-negative populations. The perforin-positive population was further divided according to the difference in MFI level as follows: fraction 1, MFI of N 22 to N 23; fraction 2, MFI of N 23 to N 24; fraction 3, MFI of N 24 to N 25; fraction 4, MFI of N 25 to N 26; fraction 5, MFI of N 26 to N 27; fraction 6, MFI of N 27 to N 28; fraction 7, MFI of N 28 to N 29; and fraction 8, MFI of N 29 to N 30. A, Coexpression of CXCR1 and perforin in CD8+ T cells from individuals U23 and U14. B, Percentage of CXCR1+ cells in the perforin-negative population and in each fraction of the perforin-positive population from five individuals.
with the effector phenotype expressed CXCR1. Indeed, six-color flow cytometric analysis showed that ~30% of HCMV-specific CD8⁺ T cells with the CD27⁺CD28⁻CD45RA⁺⁻ phenotype expressed CXCR1, but that only 10% of those with the CD27⁻CD28⁻CD45RA⁺⁻ phenotypes expressed it (Fig. 4, B and C). The ability of sorted CXCR1⁺⁺ CD8⁺ T cells to kill HCMV epitope peptide-pulsed cells was ~2-fold higher than that of total CD8⁺ T cells (Fig. 4D), suggesting that a considerable number of HCMV-specific CD8⁺ T cells with cytotoxic activity expressed CXCR1.

To determine whether chemotaxis of CXCR1⁺⁺ CD8⁺ T cells is induced by IL-8, we examined the in vitro chemotactic activity of CD8⁺ T cells purified from a healthy individual. The chemotactic activity of the cells represents as IL-8 induced migratory cells (percentage of migrated cells in absence of IL-8 was subtracted from that in presence of IL-8). Migration of purified CD8⁺ T cells was dose-dependently induced by IL-8 with 11.4% of these cells being CXCR1⁺⁺. In contrast, chemotaxis of CXCR1⁺⁺ CD8⁺ T cells, which were sorted by a cell sorter, was not induced by IL-8 (Fig. 5). Taken together, these results indicate that chemotaxis of CXCR1⁺⁺ CD8⁺ T cells is induced by IL-8. These results were confirmed in an experiment using a different individual (data not shown). Thus, CXCR1 on CD8⁺ T cells has a definite biological function.

There are some differences in the ligand specificity between the two IL-8 receptors. CXCR1 binds IL-8 and granulocyte chemotactic protein (GCP)-2 with high affinity, and growth-related oncogene and neutrophil-activating peptide-2 with low affinity, whereas CXCR2 binds IL-8, GCP-2, growth-related oncogene, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 with high affinity (16). Thus, CXCR1 is the more specific receptor for IL-8. These findings suggest that CD8⁺ T cells can respond only to IL-8 and GCP-2 in vivo, implying that effector CD8⁺ T cells may be specifically attracted to inflammatory sites where IL-8 is produced.

Recent studies in mice showed that leukotriene B₄, which is produced from mast cells, is involved in the homing of effector CD4⁺ and CD8⁺ T cells, which express BLT1, a receptor for leukotriene B₄, and BLT1 pathway in allergic inflammation. Our present data also imply a role for the IL-8-CXCR1 pathway in allergic inflammation. Further studies on effector CD8⁺ T cell homing via IL-8-CXCR1 pathway may be expected to clarify in the role of this pathway in various infectious diseases.
Acknowledgments
We thank Haruna Chatoko for technical assistance, and Sachiko Sakai for secretarial assistance.

References